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REVIEWThe neglected zoonoses—the case for integrated control and advocacyS. C. Welburn, I. Beange, M. J. Ducrotoy and A. L. Okello
Division of Infection and Pathway Medicine, Edinburgh Infectious Diseases, School of Biomedical Sciences, College of Medicine and Veterinary Medicine, The
University of Edinburgh, Edinburgh, UKAbstractThe neglected zoonotic diseases (NZDs) have been all but eradicated in wealthier countries, but remain major causes of ill-health and
mortality across Africa, Asia, and Latin America. This neglect is, in part, a consequence of under-reporting, resulting in an underestimation
of their global burden that downgrades their relevance to policy-makers and funding agencies. Increasing awareness about the causes of
NZDs and how they can be prevented could reduce the incidence of many endemic zoonoses. Addressing NZDs by targeting the animal
reservoir can deliver a double beneﬁt, as enhanced animal health means a reduced risk of infection for humans, as well as improved
livelihoods through increased animal productivity. Advocacy for NZD control is increasing, but with it comes a growing awareness that
NZD control demands activities both in the short term and over a long period of time. Moreover, despite the promise of cheap, effective
vaccines or other control tools, these endemic diseases will not be sustainably controlled in the near future without long-term ﬁnancial
commitment, particularly as disease incidence decreases and other health priorities take hold. NZD intervention costs can seem high
when compared with the public health beneﬁts alone, but these costs are easily outweighed when a full cross-sector analysis is carried out
and monetary/non-monetary beneﬁts—particularly regarding the livestock sector—are taken into account. Public–private partnerships
have recently provided advocacy for human disease control, and could prove equally effective in addressing endemic zoonoses through
harnessing social impact investments. Evidence of the disease burdens imposed on communities by the NZDs and demonstration of the
cost-effectiveness of integrated control can strengthen the case for a One Health approach to endemic zoonotic disease control.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: sue.welburn@ed.ac.ukThe origins of neglectThe Millennium Development Goals aimed, by 2015, to halve
the proportion of people living on less than a dollar a day, and
to halve the proportion of people suffering from hunger. Mil-
lennium Development Goal 6 aimed to ‘combat Tuberculosis,
HIV and AIDS, malaria (the ‘big three’) and other diseases’;Clinical Microbiology and Infection © 2015 The Authors. Published by El
This is an open access artithe major focus of these ‘other diseases’ became known as
the neglected tropical diseases (NTDs) [1]. In 2008, Molyneux
[2] suggested that these ‘other diseases’ were being ignored
by policy-makers and politicians, who over-focused on targets
around the ‘big three’ diseases; targets that were likely to prove
unattainable. The Global Fund (http://www.theglobalfund.org)
was created to ﬁnance the ﬁght against the ‘big three’, but only
limited funding was mobilized to scale up NTD interventions.
The NTDs comprise 17 viral, parasitic and bacterial in-
fections, and include dengue/severe dengue, rabies, Chagas
disease, human African trypanosomiasis (HAT), leishmaniasis,
three soil-transmitted helminth (STH) infections (ascariasis,
hookworm infection, and trichuriasis), lymphatic ﬁlariasis,
onchocerciasis (river blindness), dracunculiasis (guinea worm
disease), schistosomiasis, cysticercosis/taeniasis, foodborneClin Microbiol Infect 2015; 21: 433–443
sevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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leprosy, trachoma, and Yaws. The NTDs affect several hundred
million people (with a disease burden equivalent to malaria),
killing at least half a million annually, but continue to attract
relatively little attention from donors, policy-makers, and public
health bodies [1]. NTDs are both drivers and manifestations of
poverty and social inequality that often lead to long-term
disability [2].
In 2005, the European Parliament adopted a resolution on
‘Major and Neglected Diseases in Developing Countries’,
regretting ‘the lack of R&D into diseases which almost exclu-
sively affect poor people in developing countries’ [3]. The
resolution identiﬁed leishmaniasis, HAT, tuberculosis (TB),
Chagas disease and neurocysticercosis as causes for concern,
and called for the European Commission to broaden its
approach to other NTDs (including, among others, anthrax,
rabies and brucellosis, rabies, and echinococcosis (hydatid dis-
ease)). These neglected zoonotic diseases (NZDs) constitute a
major burden for poor rural communities [4–6].
Since then, more than a decade of advocacy for NTDs has
resulted in ambitious control and elimination targets being set
by the WHO for 2020, and several successful partnerships have
been formed to raise funds and provide advocacy for NTD
control, including the Global Programme to Eliminate
Lymphatic Filariasis (http://www.ﬁlariasis.org/) and the Global
Network for Neglected Tropical Diseases (http://
globalnetwork.org/). Such advocacy resulted in the 2012 ‘Lon-
don Declaration’ (http://unitingtocombatntds.org/resource/
london-declaration), followed by the World Health Assembly
(WHA) Resolution WHA66.12 in May 2013. WHA66.12 tar-
gets all 17 NTDs and addresses diseases as co-endemic clusters
rather than individually, marking a distinct change in our
approach to dealing with these diseases of poverty.
WHA66.12 was a turning point for advocacy for the NTDs;
however, although a number of NZDs were included (rabies,
echinococcosis (hydatid disease), leishmaniasis, Trypanosoma
brucei rhodesiense sleeping sickness, and Taenia solium cysticer-
cosis), three major bacterial NZDs (anthrax, brucellosis, and
bovine TB) were omitted. Examination of all resolutions arising
from the 66 WHAs (from 1948 to 2013) indicated that only
21 resolutions targeted one or more NZDs (<4% of the total
resolutions passed to date on infectious diseases) [7]. A
WHA resolution for all NZDs is an essential prerequisite for
advocacy [7].Costs and burden of NZDsThe impact of NZDs falls most heavily on the poor, impacting
on the health systems in which they live. Affected populationsClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceoften live in close contact with their animals, and are at risk for
infection (directly or indirectly from the animal reservoir).
Once infected, poor people have less access to the required
health information that would lead to appropriate diagnosis and
treatment. Primary healthcare facilities are often not readily
accessible in remote rural areas or in slums, and patients can ill
afford the time and money for repeated visits to a health centre.
The burden of caring for a sick family member can push
households further into poverty, and the death of a bread-
winner can devastate a rural household.
Livestock are central to survival strategies in poor house-
holds, and may be sold to meet emergency expenditures—such
as school fees, treatment and hospitalization of family members,
or food in times of shortage. Poorer people keep fewer animals
and suffer disproportionately from any illness or death of their
livestock, so that intervening to control NZDs improves both
the health of livestock and livelihoods, while at the same time
protecting human health [4–6].
‘Neglect’ is, in part, an unintended consequence of the
adoption of a system of disease prioritization, which impacts
directly on investment and funding. Calculating a global
burden of human disease (GBD), although logical, does not
offer an equitable strategy on which to base investments to
control neglected diseases. Where hospitals and clinics are
not accessible, accurate measurements of morbidity and
mortality resulting from NTDs are difﬁcult to obtain, and, for
most sub-Saharan African countries, use of the disability-
adjusted life-year (DALY) can result in systematic undervalu-
ation of NTDs [8]. Over-reliance by policy-makers on GBD
methodology in setting health priorities tends to devalue
diseases for which reliable metrics are not available [9]. King
and Bertino [8] concluded that ‘for most sub-Saharan African
countries, GDB burden has been extrapolated from scant
data taken from other locations, meaning estimates will be
only approximate with a strong tendency towards underesti-
mation of disease burden’ [9]. Efforts have been made to
improve on GDB estimates for three endemic zoonoses
(rabies, echinoccocosis, and HAT) by the use of mathematical
modelling to estimate under-reporting, but, for most NZDs,
data are scant. Whereas the socio-economic burden has been
considered for several parasitic zoonoses [10], the NZDs are
largely under-reported, which contributes to underestimation
of the disease burden. In humans, NZDs may be confused
with other diseases; for example, where malaria is present,
fevers due to brucellosis [11] or HAT [12] are often mis-
diagnosed. Although diagnostic tests are available for
screening NZDs in animal populations, many are not stan-
dardized for routine surveillance in the community in devel-
oping world settings, and the absence of a reference standard
is problematic [13,14].European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 433–443
nses/by-nc-nd/4.0/)
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not be the criterion for priority-setting, but rather that the
cost-effectiveness of interventions should be used. Cost–
beneﬁt approaches that combine health and economic beneﬁts
allow the health sector to present arguments to policy-makers
that are based on the rate of return on investment rather than
tables of DALYs; interventions against NTDs should be viewed
as investments in human capital, and form an integral part of
global poverty reduction [15]. The cost beneﬁts of in-
terventions against the NZDs in low-income countries can have
exceptionally high rankings—targeting the animal population as
the source of the disease in people can be highly cost-effective,
as interventions to control zoonoses are often best applied in
their animal hosts. The costs of such interventions, together
with animal health beneﬁts, will drive the cost-effectiveness of
intervention strategies. The impact of intervention may be
estimated in terms of DALYs prevented (notwithstanding the
caveats surrounding the DALY) or improved livestock pro-
ductivity [16].
NZDs are endemic throughout the developing world, and
can give rise to outbreaks and epidemics, with poly-infection
being common. NZDs predominantly affect individuals living
in close proximity to their animals who are exposed to disease
vectors or poorly regulated animal products.
Anthrax
The role of Bacillus anthracis in causing illness in poor livestock-
keeping communities and the impact of sudden deaths in their
herds and ﬂocks are largely ignored by policy-makers in
developing countries [4–6]. Anthrax is transmitted by spores in
contaminated soil, infecting humans via contact or consumption
of dead animals or animal products. Contamination of pasture is
the source of most animal cases in endemic countries. In ani-
mals, the disease is almost always fatal, and vaccination forms
the only basis for effective control. Global estimates of disease
burden are not provided for anthrax, as the WHO considers
that anthrax ‘is not a major public-health problem in the world
today, although occasional epidemics do occur’ [4–6]. Invest-
ment in anthrax research is maintained largely because of its
bio-terrorist potential, and remains the focus of research for
improved vaccines.
Bovine TB
The non-zoonotic Mycobacterium tuberculosis TB is the most
common form of human TB, and is one of the ‘big three’ killer
diseases worldwide. Although less is known about the zoonotic
Mycobacterium bovis TB, most cases in the developed world are
attributed to either reactivation of long-standing latent in-
fections acquired before the adoption of milk pasteurization, or
infections contracted abroad. In the developing world, whereClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiM. bovis is acquired mainly through the consumption of un-
pasteurized dairy products and from close contact with live-
stock, the contribution of M. bovis to TB epidemics of humans is
unknown. M. bovis TB is frequently found outside the lungs, and
it is almost impossible in impoverished settings to distinguish
between regular TB, which responds to common drugs
(notwithstanding the complexities arising from drug-resistant
strains), and M. bovis TB, which requires more expensive
drug therapy. In a study of a district of Tanzania, M. bovis was
isolated from 4% of cases of pulmonary TB [17]; this compares
with between 0.5% and 1.5% of all culture-conﬁrmed TB cases
in industrialized countries [18].
Brucellosis
The world’s most widespread zoonosis affects cattle, sheep,
goats, pigs, and other animals, leading to abortion, infertility,
and low milk yields. Humans acquire brucellosis from direct
contact with livestock or from drinking unpasteurized milk.
Brucellosis is a chronic disease with a risk of disabling conse-
quences, but is rarely fatal in affected humans. Brucellosis is
frequently misdiagnosed as malaria, typhoid, or venereal disease
[11]. Misdiagnosis is expensive; individuals incur signiﬁcant
expense in failing to acquire diagnosis and treatment, and fail to
conduct their daily activities, through being unwell. Across the
developing world, brucellosis is still a very common but often
neglected disease, and constitutes a major under-reported
problem. Brucellosis is the most common bacterial zoonosis
globally, with over 0.5 million new cases annually and with
prevalence rates in some countries exceeding ten cases per
100 000 population [19]. Industrialized countries have largely
controlled or eradicated brucellosis and bovine TB by using
vaccination with S19/Rev1 (for brucellosis) and test and
slaughter (T&S) plus ﬁnancial compensation (for both zoono-
ses) [20]. Dealing with the problem in livestock alleviates the
problem for humans, but countries in the developing world may
not have the requisite level of organization of veterinary ser-
vices or the ﬁnancial resources to fund a vaccination campaign,
or be willing to compensate famers for culling livestock,
without which vaccination and T&S policies cannot be
implemented.
T. solium neurocysticercosis
The helminth parasite T. solium is associated with poverty,
particularly poor sanitation, and is endemic to South and
Central America, China, the Indian subcontinent, Southeast
Asia, and sub-Saharan Africa. An estimated 2.5 million people
are infected with T. solium, and there are 50 000 deaths annually
due to neurocysticercosis [21]. The global burden of cysticer-
cosis (symptomatic) in the endemic zone of Latin America was
estimated to be 400 000 cases in 75 million people [22]. Whenof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 433–443
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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owing to social stigmatization and discrimination, which are
barriers to diagnosis and treatment. In most Asian countries,
accurate data on T. solium are scarce, but it is common in parts
of Indonesia, China, India, Vietnam, and Laos [22,23]. The
prevalence of cysticercosis in pigs in Latin America varies from
<2% to >75%, with an average of 17% [24]. Up to 45% of pigs
are infected in some villages in Uganda, and in many countries
cysticercosis rates in pigs are 10% [25]. Neurocysticercosis is
considered to be the most common preventable cause of ac-
quired epilepsy in the developing world, and the most impor-
tant neurological disease of parasitic origin in humans. With the
rise in pig production in smallholder farms across the devel-
oping world, neurocysticercosis is increasingly becoming an
emerging public health problem. Cases tend to be clustered,
and late-onset epilepsy generates a high socio-economic burden
for poor families in the endemic areas [26].
Cystic echinococcosis (CE)
CE is an emerging zoonotic parasitic disease where small ru-
minants and dogs are reared together, and is responsible for
debilitating, potentially life-threatening human disease. Budke
et al. estimated the global burden of CE in both humans and
livestock, taking into account under-reporting [27]. Globally,
human-associated annual economic losses (including medical
costs, wage losses, and postoperative deaths) were estimated at
US$1.9 billion, with livestock losses— largely in countries with
functional meat hygiene systems, owing to the economic impact
of organ condemnation—being US$2.19 billion. Although
several species of Echinococcus exist, Echinococcus granulosus
tapeworm infection is spread between dogs and small ruminants,
with people becoming infected through eating tapeworm eggs.
Human transmission occurs through the consumption of
contaminated raw vegetables or from handling infected dogs.
Untreated cysts in humans (often in the liver or kidneys) can
grow to be very large, requiring expensive—and often high-
risk—surgery for their removal. The ongoing human impact is
substantial, manifesting as missed working days, and the risk of
relapse or death, particularly if large cysts burst before surgery
can be performed. There have been improvements in the diag-
nosis and treatment of human and animal cystic echinococcosis,
and the diagnosis of canine echinococcosis, and trials of vaccines
against E. granulosus in animals are underway [28,29].
Leishmaniasis
This vector-borne, protozoan parasitic disease is considered to
be the third most important vector-borne disease globally, with
an estimated 350 million people being at risk in 88 countries, 12
million cases worldwide, and approximately 50 000 deaths
every year [30]. Transmission is mostly zoonotic (via dogs andClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licesmall rodents), but the disease can be spread between humans.
Cutaneous leishmaniasis, the most common form, is non-fatal,
but can cause extensive skin ulceration, leading to terrible
facial disﬁgurement and stigmatization. Visceral leishmaniasis is a
chronic systemic disease that affects the internal organs and can
be fatal if left untreated. WHO data estimate the leishmaniases
to contribute 2.4 million DALYs [31], but current methods of
assessing disease burden fail to account for variations in clinical
presentation, which often demand intense medical in-
terventions within small foci. Reliable data on the incidence,
duration and impact of the various syndromes associated with
leishmaniasis are not available [32].
Rabies
Rabies is a notoriously fatal zoonotic disease; it is caused by a
virus that enters the body following the bite of an infected ani-
mal, and migrates to the brain. Data on incidence of rabies are
difﬁcult to obtain, and under-reporting is a signiﬁcant factor. To
quantify the burden of rabies in Africa and Asia and to allow for
under-reporting, a model was developed that used dog-bite data
to infer numbers of human deaths [33]. The threshold density
for rabies persistence was calculated to be 4.5 dogs/km2. Fifty-
ﬁve thousand human deaths from rabies per year in Africa and
Asia produce a total DALY score of 1.7 million and a cost of
US$583 million. Costs are borne almost entirely by people in the
developing world, where >99% of all fatalities occur [5]. Dog
vaccination is a proven, simple, low-cost intervention for
effective control in many rabies-endemic countries.
Zoonotic sleeping sickness
Trypanosoma brucei rhodesiense causes acute sleeping sickness
(Rhodesian HAT (rHAT)), and infects a range of wildlife [34]
and domestic animals [35]. Cattle constitute the most impor-
tant reservoir in East Africa and southern Africa [36], and are
responsible for the spread of rHAT in Uganda [37,38]. Un-
treated, the disease is always fatal in humans, but has little or no
effect on the productivity of indigenous cattle. Under-reporting
is common; a study in Uganda found that 92% of sleeping
sickness deaths are not reported [12]. Sleeping sickness cases in
Uganda are responsible for more patient admission time than all
other infectious diseases other than malaria, severe malaria
accounting for approximately 40% of hospital days and HAT
30%. The burden of HAT is poorly reﬂected in many existing
assessments [39].Integrated control of the NZDsSustainable health improvements in resource-poor countries
require cross-sectoral, integrated, participatory or One HealthEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 433–443
nses/by-nc-nd/4.0/)
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measured as the proportion of the human and/or animal pop-
ulation covered and cured or protected against a disease. For
any drug/vaccine intervention, a range of biological, cultural,
sociological, political and ecological factors are involved,
including availability, accessibility, affordability, efﬁcacy, accept-
ability, diagnostic accuracy, and provider and consumer
compliance. Determinants of effectiveness of surveillance and
interventions at different scales, from the household to the
government level, can be assessed through a combination of
quantitative and qualitative epidemiological, social and anthro-
pological methods to produce a quantiﬁable framework of
effectiveness [40,41]. The synergistic beneﬁts of close interplay
between human and animal health have been demonstrated in a
number of settings. Integrated study designs for simultaneous
investigation of health status in humans and animals, for rapid
identiﬁcation of the source of a zoonotic disease, have been
developed (for example, in Kyrgyzstan, the seroprevalence of
human brucellosis is closely related to keeping sheep [42], and
frameworks developed to assess societal costs [43] have shown
that it is possible to eliminate human brucellosis through
effective interventions in animals).
The NZDs can be tackled in an integrated manner by
focusing on a point of epidemiological or practical interaction
that can beneﬁt human and animal health. The European
Commission-funded project Integrated Control of Neglected
Zoonoses in Africa (ICONZ) has been evaluating the cost-
effectiveness of a range of strategies based on clustering dis-
eases and targeting interventions for bacterial (anthrax, bovine
TB, and brucellosis), dog/small ruminant-associated (rabies,
leishmaniasis and hydatid disease, and pig-associated disease—
cysticercosis and neurocysticercosis) and vector-borne (zoo-
notic rHAT) (http://www.iconzafrica.org) diseases.
Anthrax, bovine TB, and brucellosis
Although they are controlled across most of Europe, these
bacterial zoonoses, which infect livestock and humans, coexist
in many communities, and still present a signiﬁcant global
challenge. Integrated surveillance and control for these zoo-
noses could be implemented and offer signiﬁcant value,
particularly in the developing world, considering the similar risk
factors between these diseases. Brucellosis, bovine TB and
anthrax are transmitted via direct contact with infected animals.
Unpasteurized milk/milk products and abortion materials pre-
sent major risks for the acquisition of brucellosis and bovine TB
in poor communities. These bacterial NZDs impose a dual
burden in affected communities, in terms of animal productivity
losses and impact on human health (although the human burden
is often poorly characterized, owing to underdiagnosis and
under-reporting) [44]. Bacterial zoonoses are re-emergingClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiacross sub-Saharan Africa, owing to the coexistence of pasto-
ralist movements and an increase in intensive management
arising from intensiﬁcation of livestock production systems,
with far-reaching social and political implications [45]. A recent
study found that most cases of brucellosis in Kampala, Uganda
resulted from consumption of raw milk transported from peri-
urban areas of Kampala and/or dairy production areas outside
Kampala [46].
Brucellosis and bovine TB screening could be integrated by
use of the Rose Bengal test in parallel with bovine TB skin
testing. The Rose Bengal test is a cheap, simple, agglutination
test, with high sensitivity. The intradermal bovine TB skin test is
read after 48 h, when the results of the brucellosis test would
also be available, and farmers and communities could be
informed of both. Testing of at-risk humans could also save the
costs of multiple community visits, but the logistical difﬁculties
of this approach still present problems, particularly in extensive
systems.
There is no vaccine for bovine TB, and T&S is not usually
applied in Africa, where, without compensation, communities
are not willing to give up an animal for slaughter. There are
effective vaccines for brucellosis—S19 for cattle, and Rev1 for
small ruminants—and communities are willing to pay for
vaccination. Vaccination can be implemented in intensive and
commercial farms, but delivery across much of Africa remains
challenging. The development of a conjunctival form of S19
would increase adoption in pastoralist communities [44].
In the absence of T&S policies, integrated community
participatory approaches may prove useful for the control of
brucellosis and bovine TB. Participatory and trans-disciplinary
approaches for the development of locally adapted in-
terventions against brucellosis and bovine TB have been used to
develop health interventions in mobile pastoralist communities
in Chad and Mongolia [46–48].
Zoonotic trypanosomiasis and tick-borne animal
diseases
rHAT, caused by Trypanosoma brucei rhodesiense, is endemic in
several foci across East Africa [49,50]. Sleeping sickness can be
cured if diagnosed and treated early, but most of those
affected live in remote areas with poor access to healthcare
services [51]. A range of wildlife can act as reservoirs of rHAT
[34], but in Uganda the reservoir of infection comprises do-
mestic cattle [35,36]. The northwards migration of infected
cattle from the endemic sleeping sickness foci has resulted in a
large expansion of the rHAT focus, which now borders the
Trypanosoma brucei gambiense (chronic) HAT focus [38,51].
Convergence of two forms of HAT will have major implica-
tions for the management of human sleeping sickness in
Uganda [52,53].of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 433–443
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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desian sleeping sickness has long been recognized but largely
ignored. Identiﬁcation of human infective parasites in livestock
is performed with a molecular marker, the SRA gene [35].
Studies of endemic foci in Uganda have shown up to 40% of
cattle carrying Trypanosoma brucei rhodesiense [36]. Given the
contribution of the animal reservoir to transmission of rHAT,
treatment of livestock to remove the parasites followed by
vector control to prevent re-infection is the preferred option
[37,54]. The removal of all trypanosomes from cattle requires
injection of a low-cost (US$0.5) trypanocidal drug. Animals can
be kept free from re-infection with human-infective and animal-
infective trypanosomes by treatment with long-lasting formu-
lations of synthetic pyrethroids. Restricted application of
insecticide to only the legs and belly of the bovine host, where
most tsetse ﬂies feed [55], has brought trypanosomiasis control
within the reach of poor farmers in Africa. Furthermore,
insecticidal treatment of only 20% of a cattle population is
sufﬁcient to control both rHAT and animal trypanosomes in
that population [56,57]. If insecticide is also applied to the ears,
then restricted application of insecticide also removes ticks,
reducing the challenge from East Coast fever, Babesia, and
anaplasmosis, and this is the main driver for farmers to maintain
monthly application of insecticides [58].
Interventions targeted at dogs and small ruminants
Three NZDs (rabies, leishmaniasis, and hydatid disease) can be
addressed by targeting dogs. Vaccination for rabies is a tried and
tested intervention, with high cost/beneﬁt ratios. Although
there is an increasing commitment to eliminate rabies from
developing countries with annual rounds of mass dog vaccina-
tion, this target is challenging. The Global Alliance for Rabies
Control, established in 2005, has raised awareness, supported
control programmes, and promoted educational initiatives
(http://www.rabiescontrol.net/). Community rabies vaccination
campaigns could be combined with interventions for hydati-
dosis or leishmaniasis, offering added value. There is now some
activity ongoing in most countries, but even countries with the
resources do not often meet and sustain these rates, and a
permanent plan of action is needed to organize rabies vacci-
nations as part of the annual calendar. KwaZulu province in
South Africa recently completed its ﬁrst year without a single
case of human rabies, thanks to a dog rabies control pro-
gramme supported by the Bill and Melinda Gates Foundation.
Tanzania embarked on an ambitious programme to repeatedly
vaccinate dogs in 28 districts, but willingness to participate in
vaccination was negated by fear of rabies, high medical treat-
ment costs, and the threat of dog-culling. Problems with
campaign mobilization, timing, the location of central points,
equipment and staff and project organization created barriersClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceto community compliance [59]. In poor regions, where canine
rabies continues to be highly endemic, simply increasing
awareness about the cause of the disease and how it may be
prevented could reduce its incidence [60], and such campaigns
could be extended to other dog zoonoses in these regions.
Leishmaniasis
The sand ﬂy transmits Leishmania infantum from dogs to
humans, and deltamethrin-impregnated dog collars for control
have proved successful. Modelling has indicated that
community-wide use of treated dog collars could be more
effective than a dog-culling strategy, especially where trans-
mission rates are high, although the impact of collaring is
dependent on collar coverage and the rate of loss of collars
[32]. An over 80% reduction in canine incidence was shown in
trials of treated dog collars in Italy [61,62]. Monthly application
of pour-on insecticides was also effective in reducing canine
incidence in Italy [62] and Brazil [63].
E. granulosus
CE transmission can be prevented by deworming dogs, stray
dog population control, and preventing dogs from eating cyst-
infected livestock viscera. A number of low-cost approaches
could be used for CE control, including preventing dogs from
eating openly discarded cysts during the process of backyard
slaughter and in established government slaughterhouses [64].
Dog interventions for this group of NZDs demand a clear
understanding of the role of the dog in the community, which,
in turn, will inﬂuence the mode of delivery and practicality of
achieving a high level of vaccination coverage. During annual
rabies vaccination campaigns, it would be straightforward to use
this single community visit to also de-worm the dogs and apply
insecticidal collars in areas where hydatid and leishmaniasis
prevail. This offers a practical and economical way of inter-
rupting disease transmission, reducing risk, and delivering
messages about overall dog management, health, and welfare.
Owned dogs can easily be vaccinated, wormed, and collared,
but the village dogs (belonging to everyone) are more difﬁcult
to catch and treat [59]. For stray animals, interventions may
include dog population control/culling, oral vaccination in baits
to prevent rabies, and slaughterhouse legislation for destruction
of cyst-infected livestock viscera to prevent stray dogs having
access to cysts.
Pig-associated zoonoses
T. solium cysticercosis was declared to be eradicable by the
International Task Force for Disease Eradication in 1993, but,
despite a relatively uncomplicated epidemiology and progress in
operational research, global eradication of T. solium is consid-
ered to be unlikely in the near future [21]. It is clear thatEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 433–443
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implemented simultaneously in both pigs and humans. Where
open defecation is the norm, pigs and people are caught in a
vicious cycle of T. solium cysticercosis/taeniasis. The most sus-
tainable solution is to stop T. solium transmission from human
to pigs with the provision of clean water and sanitation com-
bined with veterinary sanitary measures, such as meat inspec-
tion and treatment of infected animals. Repeated mass drug
administration (MDA) of antihelminthic drugs such as prazi-
quantel, niclosamide and albendazole to human T. solium car-
riers has been applied in mass treatment programmes in China
and Latin America [21]. Integration of T. solium control with
existing MDA programmes for STHs or other parasitic NTD-
causing organisms such as foodborne trematodes or those
causing schistosomiasis offers the opportunity to capitalize on
existing frameworks for control under larger NTD pro-
grammes. Diagnosis of the presence of adult tapeworms relies
on the detection of parasite antigens in faeces (coproantigens),
and tests have good speciﬁcity and sensitivity [65]. There have
been advances in the diagnosis of T. solium infections with im-
munodiagnostics [21]; serological tests indicate whether the
cysts carried in people or animals are alive or dead (treatment
is appropriate for live cysts). Recombinant parasite antigen
vaccines have been developed that could prevent T. solium
transmission [30], but these are not yet commercially available.
Pig vaccines may prove useful in commercial settings, but
adequate take-up of such vaccines by poor farmers in rural
areas where pigs are left free to run and feed on waste seems
unlikely.
Open defecation is a key indicator of socio-economic
marginalization [66,67], with global inequalities being reﬂected
in how and where a person defecates. Today, 2.6 billion people
lack improved sanitation, and 1.1 billion of these practise open
defecation, which is believed to be responsible for the death of
one-and-a-half million children annually [68]. Community-led
total sanitation (CLTS) aims to mobilize a community to a
point where open defecation is no longer practised and the
village can be declared ‘open defecation free’ [69]. CLTS is
premised on the idea that ‘once people are convinced about the
need for sanitation, they construct their own toilets according
to resources available’ [70]. Facilitators drive ‘self-realization’
by using ‘local and crude words for “shit” and “shitting” …
rather than polite terms’ [70]; disgust, shame and fear drive the
community towards collective action [71]. If open defecation
free status can be maintained, CLTS should impact on cysti-
cercosis, STH diseases, and other diseases arising from poor
sanitation, e.g. dysentery and cholera.
Changing human behaviour is difﬁcult to achieve, especially
for zoonotic infections, in which years may pass between
infection and clinical symptoms. Communities are unaware thatClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiwhite nodules in pigs and epilepsy in humans are linked, and
may relate epilepsy to witchcraft, and white nodules in pigs to
bad practice in farming. Village slaughter and the absence of
meat inspection mean that infected pigs enter the food chain.
The economic beneﬁt of selling ‘clean’ meat is non-existent, and
farmers and communities need to be able to recognize unin-
fected meat. Pig management practices (conﬁnement and
treating with oxfendazol) can contribute to breaking the
T. solium cycle, and also impact on African swine fever and
gastrointestinal parasites; however, the broader socio-
economic and welfare impacts of pig conﬁnement must be
considered before this control method is promoted. Health
education can contribute to behaviour change. ‘Vicious Worm’
(http://www.theviciousworm.org) is an interactive education
tool with three layers of health information: the city—aimed at
decision-makers; the town—aimed at health practitioners; and
the village—aimed at local communities [72].AdvocacyThe WHO Neglected Zoonotic Disease conference series has
signiﬁcantly raised the proﬁle of NZDs, drawing attention to the
relationship between poverty and the emergence or re-
emergence of neglected zoonotic diseases, particularly:
anthrax; bovine TB; brucellosis; cysticercosis; CE; rabies; and
HAT [4–6]. Participants of the most recent meeting ‘From
Advocacy to Action’, held at the WHO headquarters in
November 2014 (http://www.who.int/neglected_diseases/
zoonoses/fourth_international_nzd_meeting/en/) agreed that,
although ‘challenges undoubtedly remain’ regarding the
currently available toolbox for NZD control, the time is right to
move forwards with the implementation of large-scale control
programmes. Large European Commission investments for the
NZDs now include: ICONZ (http://iconz.africa.org); Advocacy
for the Neglected Zoonoses (ADVANZ; http://www.advanz.
org); and the European Technology Platform for Global Ani-
mal Health (http://www.ifaheurope.org/EUPlatform/) [73].
There is a perception that, if NZDs achieve a higher proﬁle
with government and donors and if we can show that it is
feasible and cost-effective to intervene, funds will ﬂow and
control will follow. Several NZDs have achieved such a high
proﬁle, but remain neglected. From an economic standpoint,
the costs and beneﬁts of controlling NZDs support the
implementation of a control programme—not to mention the
ethical responsibility of the state in ensuring optimal human
health for its citizens. However, to take action, policy-makers
need to know the cost and burden of the disease, the best
method of controlling it, how long this will take, the full eco-
nomic cost of control, and options for apportioning costs.of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 433–443
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Global Alliance for Rabies Control, but still kills an estimated
55 000 people every year, mainly in Africa and Asia, despite
cheap and effective vaccines being available for humans, dogs,
and even for wildlife. Among all of the neglected NZDs, dog
rabies elimination is the lowest hanging fruit. However, even
with these excellent, cheap and effective dog vaccines available,
and with burdens and costs well understood, there is no
guarantee that elimination will be easily achieved [59]. The
costs of intervention in an animal reservoir may seem high as
compared with the public health beneﬁts alone, and proﬁtability
may not be obvious from a single-sector perspective. For
rabies, from a human health perspective, a dog bite wound
requires cleaning, and a post-exposure treatment (PET) vacci-
nation is essential, but expensive. As dog-to-dog transmission
drives rabies epidemics, PET alone will not eliminate rabies.
From an animal health perspective, rabies in cattle, and not
dogs, is important, so national rabies vaccination programmes
are not prioritized. For rabies, the cost beneﬁt of vaccinating
dogs may take many years to be realized, and requires universal
high coverage to be achieved annually. In N’Djamena in Chad,
the cumulative cost of dog rabies mass vaccination and human
PET was equal to the cumulative cost of PET alone after 6 years,
and only became more cost-effective after 7 years [74].
Interventions for NZD in the animal reservoir (mass vacci-
nation, drug treatment, and education) must be supported and
operationalized across health and agriculture ministries. Long-
term national and regional plans for elimination demand sig-
niﬁcant buy-in from both human and animal health sectors.
When a full cross-sector analysis is undertaken and all stake-
holder beneﬁts (monetary/non-monetary) are taken into ac-
count, interventions for NZDs can become highly cost-effective
For example, when the costs of brucellosis mass vaccination are
shared between the health and livestock sectors in proportion
to their beneﬁts, brucellosis control becomes cost-effective
[75].
Communicating information to governments, donor bodies
and communities is key to control. Provider and/or commercial
interest add a political dimension to disease prioritization or
neglect, and there is now concern about the public health
threat of new, re-emerging and neglected zoonoses in the
industrialized world [76,77]. Identiﬁcation of gaps can help in
targeting funds to the areas of greatest need. The Neglected
Zoonoses Research Database http://www.zoonosis.ac.uk/
ICONZ/ provides a global picture of funding and research for
eight NZDs, and includes a publications database, a research
projects database, and a funders database.
Interventions for NZD control require long-term commit-
ments to realize the economic beneﬁts. For example, elimina-
tion of human CE requires a long-term, multi-sector plan thatClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licebuilds on strong political mobilization and an integrated infra-
structure, and behaviour change interventions, which, even in
the most favourable environments, may take up to 20 years
[29]. Programmes may require signiﬁcant front-loading (estab-
lishment of vaccine banks; drugs and logistics for mass treat-
ments; and educational campaigns). These long-term and often
front-loaded programmes can be difﬁcult to support within
government or donor funding cycles. Often, once the number
of cases begins to decrease, systems for surveillance and con-
trol become difﬁcult to sustain.
Stamp Out Sleeping Sickness in Uganda (http://www.
stampoutsleepingsickness.org) has shown that it is possible
to keep districts affected by zoonotic HAT clear of infection
by removing the reservoir of infection with mass treatments of
cattle with trypanocides, and by preventing re-infection by the
use of insecticides. This has large cost beneﬁts, and an in-
vestment of $US40 million could tackle the whole at-risk area
and remove the risk of zoonotic HAT— funds that Uganda
does not have. An innovative funding mechanism provides
hope for sustainable sleeping sickness control; use of a
Development Impact Bonds (DIB) private investment could
raise the funds needed for large-scale, long-term delivery
http://www.cgdev.org/working-group/development-impact-
bond-working-group. Private investors provide up-front fund-
ing for the DIB and, as with other investments, take on the
risk of reward or loss. Funds are directed to implement the
programme, and outcomes are assessed independently. If ob-
jectives are not met, investors absorb the loss, but if they are
achieved, international donors repay the private investors with
interest. Investors have a strong incentive to manage their risk
by bringing rigour and discipline to the DIB process. This in-
creases the probabilities of both achieving the development
outcome and of generating a ﬁnancial return. This novel
funding mechanism is also being explored for other NZDs,
such as rabies.ConclusionThere is widespread acknowledgement of the value of an in-
tegrated approach to tackling the NZDs, but agreement is now
needed on the politics and ﬁnance. Policy-makers need to know
the current cost and burden of the disease, the best method of
controlling it, the full economic cost of control, and the impacts
on their communities. However, in many poorer countries,
putting resources into the surveillance and treatment of animal
populations rarely meets with much support, despite that fact
that improved human and animal health can play a major role in
promoting food security and eradicating poverty [77,78]. Given
the institutional limitations in the veterinary and human publicEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 433–443
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from adopting a One Health approach that supports inter-
sector working practices [78,79].
More often than not, the cheapest and most effective strategy
for dealing with zoonotic diseases is to control infection in the
animal population, and for those NZDs for which the human
disease cannot be maintained in the absence of an animal
reservoir, for which effective tools are available, and for which
signiﬁcant advocacy has been raised, elimination may be possible,
e.g. zoonotic HAT and rabies [16]. The solution may be a top-
down approach—such as a vaccination programme or
MDA—but sustained control is about working within the
community to change behaviour and practice. New funding
models offer the potential for raising the resources required,
enabling greater attention to be paid to navigating the local re-
alities in planning and implementation that are essential for
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